Clinical Commissioning Policy Proposition: Bendamustine with rituximab for relapsed indolent non-Hodgkin’s lymphoma (all ages)

This consultation is now closed…

Unfortunately, this consultation is now closed and no more online responses will be accepted.

Return to consultation overview